Read More

Cannabis Stocks And ETFs Trading Higher As Government Recommendations Ignite Hope For Industry

Cannabis stocks and ETFs opened higher on Tuesday following the release of documents related to the Department of Health and Human Service's (HHS) review of cannabis. Investors are optimistic about potential regulatory changes that could benefit the cannabis industry after the US government released 252 pages of documents confirming the HHS's recommendation that the DEA reschedule cannabis as Schedule III under the Controlled Substances Act. The documents state that cannabis has a currently accepted medical use in treatment and potential for abuse less than drugs in Schedules I and II. In August, the Assistant Secretary for Health wrote a letter to the DEA calling for marijuana to be reclassified. The Secretary of HHS has confirmed that his department shared a comprehensive scientific review with the DEA in response to President Joe Biden's scheduling directive.

ACB

Read More

Equity Research Looks At Undervalued E-Commerce Weed Stock: Mapping The Online Platform’s Potential

In a detailed equity research report, Zuanic & Associates offer a neutral perspective on WM Technology (NASDAQ: MAPS), a leading player in the cannabis sector, highlighting its unique market position and prospects.

MAPS

Read More

“Congressman Steve Cohen (D-TN) Tells DEA To Reschedule Marijuana ‘As Swiftly As Possible’; Says “I Urge You, In The Strongest Possible Way, To Follow Through On HHS’s Recommendation” To Move Cannabis To Schedule III.” – Marijuana Moment

https://www.marijuanamoment.net/congressman-tells-dea-to-reschedule-marijuana-as-swiftly-as-possible/A Democratic congressman is calling on the Drug Enforcement Administration (DEA) to complete its marijuana review "as

ACB